We are uniquely equipped to advise organisations operating in the devices and medtech space. With one of the most highly regarded life sciences practices in the world, and a market-leading technology practice, convergence is an exciting area for us - and we are always at the forefront of developments where digital technology and healthcare come together.

With plenty of scientists and technology enthusiasts among our lawyers, we are not only able to keep up with industry trends but we are, perhaps more importantly, able to understand the science and technology behind them as well as the legal issues that may arise.  From traditional devices, instruments and equipment, to health apps and algorithm development, to the collection and use of healthcare data and the development of new software and technologies, we are able to draw on the depth of knowledge and experience of our leading life sciences and technology practices to offer a complete legal service.

Key contacts

Alex Denoon

Contact

Claire Smith

Contact

Experience

For many years, we have advised Smith & Nephew, one of the world’s leading medical devices and medical technology companies. Our work has included patent litigation in relation to wound healing products and technology, M&A, regulatory advice, and procurement of IT and digital technologies and services.

Our client, a leading healthcare provider, wanted to offer its patients a seamless digital service to access their medical information, book appointments and manage their payments. We supported our client’s initial investment into the Silicon Valley start-up it was partnering with, advised on IP licensing and IT hosting arrangements, as well as data protection and regulatory compliance.

Advising Genomics England (GEL) on the 100,000 Genome Project, a project backed by the UK Government to sequence the DNA of 100,000 NHS patients.  Over more than five years, we have advised GEL on its IP and commercialisation strategy for implementing the largest sequencing project in the world and led negotiations for the various data, IT, technology and IP commercialisation projects, as well as assisting on real estate transactions to house the sequencing and technology hardware and providing employment and corporate advisory services to the organisation.

We advised ResMed, the world’s leading manufacturer of medical respiratory devices, in defence of UK revocation proceedings brought by a significant competitor in relation to three of ResMed’s patents. The dispute related to products for diagnosing and treating sleep-related respiratory disorders and involved our coordinating parallel litigation in nine jurisdictions.

Our client, one of the most high-profile creators of artificial intelligence in the world, regularly seeks our advice in connection with regulatory compliance for novel products in the healthcare arena.

Latest articles

What others say

“Bristows was a valued partner in the success of making our vision become a reality.”

Stephanie Morris, Director of Industry Partnerships and Commercialisation at Imperial College London

“They enabled a very positive conclusion to the overall deal.”

Richard Fagan, Director of BioPharma at UCL Business

“Their expertise made them the perfect partner to work with on the highly complex Apollo transaction.”

Richard Fagan, Director of BioPharma at UCL Business

“UCLB has worked with Bristows for over 25 years, in relation to intellectual property licensing transactions as well as corporate transactions such as spinout formation.”

Richard Fagan, Director of BioPharma at UCL Business

“Bristows’ knowledge of the life sciences market and players, as well as their licensing expertise, was invaluable as we navigated this complex transaction.”

Iain Thomas, Cambridge Enterprise’s Head of Life Sciences

Recent rankings and awards

Life Sciences – Band 1
Chambers and Partners UK 2019

Life Sciences: IP/Patent Litigation - Band 1
Chambers and Partners UK 2019

Life Sciences: Transactional - Band 2
Chambers and Partners UK 2019

Pharmaceuticals and Biotechnology - Top tier
Legal 500 2019

Life Sciences - Band 3
Chambers and Partners Europe 2019